Chronic Eosinophilic Leukemia

Modern treatment approaches, including therapeutic phlebotomy, low-dose aspirin, and cytoreductive therapies (hydroxyurea, interferon-α formulations, and ruxolitinib), have reduced blood cell counts and thrombotic risk, yet concerns about treatment-associated cardiovascular toxicity have emerged. Recent cardio-oncology guidelines emphasize structured monitoring for cancer therapy-related cardiovascular toxicity. This mini review summarizes the cardiovascular burden of PV, therapeutic strategies to mitigate risk, and emerging perspectives on cardiotoxicity-including a recently reported case of reversible left ventricular dysfunction associated with ropeginterferon α-2b.

Overall, our results support a pro-proliferative role of DARS in human MPN cell models. DARS depletion was associated with PI3K/AKT-related transcriptional and metabolic alterations, and reactivation of PI3K/AKT partially rescued the phenotypic changes induced by DARS depletion.

Phase III data from PROUD-PV (NCT01949805; EudraCT, 2012-005259-18) and its phase IIIb extension, CONTINUATION-PV (NCT02218047; EudraCT, 2014-001357-17), demonstrate that ropeg, compared with hydroxyurea, achieves hematologic response more slowly but provides greater, more durable responses after ∼18 months, underscoring the importance of long-term adherence. Early adverse events can challenge adherence, emphasizing the need for proactive symptom management. This review offers evidence- and experience-based perspectives on long-term ropeg treatment and adverse event management to support adherence and maximize therapeutic benefit in PV.

The patient was treated with corticosteroids, anticoagulation, and Imatinib...Recognizing molecularly driven eosinophilic disorders is essential, as targeted treatment can significantly improve prognosis. The presence of the Fip1-Like1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRα) fusion gene is a rare cause of hypereosinophilic syndrome requiring a distinct therapeutic approach.

Integrated clinicopathologic and molecular assessment reclassified most HEPU cases as reactive or clonal, with only 39% remaining idiopathic. Myeloid NGS frequently identifies clonal variants critical for refining HE classification, although results require cautious interpretation within the WHO-HAEM5 and ICC 2022 context.

Emerging combination strategies and their clinical development will be reviewed here, including investigations that pair JAKi therapy with BCL-2 family inhibitors, BET inhibitors, restored p53 cell death signals, telomerase inhibitors, PIM1 kinase inhibitors, and mutant CALR targeted therapies. While several combination clinical trials suggest improved spleen and symptom responses and the possibility of disease modification, toxicity profiles and optimal sequencing remain areas of active investigation.

We report a 15-year-old boy with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia who initially presented with persistent hemorrhagic crusts on the lower lip, an uncommon mucocutaneous manifestation resulting from thrombotic aggregates of eosinophil granule proteins. This case is followed by a systematic literature review of pediatric FIP1L1-PDGFRA-positive HES to further characterize its clinical features and outcomes in children.

A 25-year-old woman with pre-existing Hashimoto's thyroiditis developed progressive bilateral nodular scleritis with anterior uveitis that proved completely refractory to high-dose corticosteroids, methotrexate, and conventional disease-modifying antirheumatic drugs, along with papilledema and granulomatous rosacea, suggesting systemic inflammation. Recognition of this molecular target enabled precision therapy with fostamatinib, a spleen tyrosine kinase (Syk) inhibitor, combined with adalimumab, a tumor necrosis factor-alpha (TNF-α) inhibitor, resulting in complete and sustained remission of all inflammatory manifestations over 18 months of follow-up. This case underscores the critical importance of maintaining high clinical suspicion for paraneoplastic autoimmune syndromes in patients with treatment-refractory inflammatory conditions, particularly when accompanied by atypical systemic or unexplained laboratory findings, and demonstrates that molecularly targeted precision medicine approaches can transform treatment outcomes in complex paraneoplastic rheumatic disorders.

While no JAK inhibitor has demonstrated clear disease-modifying effects in MF, pacritinib's non-myelosuppressive profile, unique activity against IRAK1, and potential anemia benefit via ACVR1 inhibition suggests potential utility as a backbone for future combination strategies. Ongoing and future studies will be critical to further define its role in phenotype-driven MF management.

The FMF-02 trial is the first randomized phase IIb study directly comparing the novel inhibitor FM against RUX. Its findings are expected to generate pivotal evidence regarding whether FM offers superior or differentiated clinical benefits, thereby informing its potential as a frontline therapy for intermediate- to high-risk MF and guiding the design of future phase III studies.